RE:RE:RE:RE:RE:The Head, The Heart and The Gut
A tremendous amount of value has been created on a shoestring budget, & I have 100% confidence in the science & the clinical data moving forward. The strong data/drug versatility/reduced risk & attractive pricing will certainly give us some leverage at the negotiation table. However, it generally takes lots of cash to have an upper hand. Having the ability to say "no" to Big Pharma can alone be worth north of $1 billion...all imo. A good outcome for me would be a more friendly cash raise (post BTD/AA) & have at least one additional Ph1b under our belts for leverage sake.
It's been great to see such a small company work its independence, but at the end of the day, Pharma negotiations always start with the data but end with strength of cash...I hope management represents shareholders well. Some may say they have earned a 2nd chance. Good luck...
Had to make some grammatical corrections : ).